维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

12篇 您的检索式：作者名="Nakazuru"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Optimal indications for second-line chemotherapy in advanced gastric cancer显示文摘	Hasegawa H Fujitani K Nakazuru S		0，，04：	1
	2	Efficacy and safety of metronidazole injection for the treatment of infectious peritonitis, abdominal abscess and pel- vic inflammatory diseases in Japan 显示文摘	Hiroshige Mikamo Miyako Matsumizu Yoshiomi Nakazuru Masa- hito Nagashima	2014	Journal of Infection and Chemotherapy2014，21，2：	1
	3	Gastrointestinal:Unusual duodenal follicular lymphoma observed by magnifying endoscopy with narrow-bandimaging显示文摘	Nakazuru S Yoshio T Suemura S	2013	J Gastroenterol Hepatol2013，28，8：	1
	4	Case of primaryhepatic neuroendocrine carcinoma diagnosed by needle biopsy显示文摘	Hasegawa H Kuzushita N Nakazuru S	2010	Nihon Shokakibyo Gakkai Zasshi2010，107，12：	1
	5	Optimal indications for second-line chemotherapy in advanced gastric cancer显示文摘	Hiroko Hasegawa Kazumasa Fujitani Shoichi Nakazuru Motohiro Hirao Eiji Mita Toshimasa Tsujinaka	2012	Anti-Cancer Drugs2012，，4：	1
	6	Case of primary hepatic neuroendocrine carcinoma diagnosed by needle biopsy显示文摘	Hasegawa H Kuzushita N Nakazuru S	2010	Nihon Shokakibyo Gakkai Zasshi2010，107，12：	1
	7	Optimal indications for second-line chemotherapy in advanced gastric cancer显示文摘	Hasegawa H Fujitani K Nakazuru S		0，，04：	1
	8	Efficacy and safety of a single oral 150 mg dose of fluconazole for the treatment of vulvovaginalcandicliasis in Japan显示文摘	Mikamo H Matsumizu M Nakazuru Y Okayama A Nagashima M	2015	J Infect Chemother2015，21，：	1
	9	Effect of twice daily intravenous interferon-beta booster treatment given for two weeks in patients still HCV-RNA positive at week 24 of peginterferon a2b plus ribavirin therapy 显示文摘	Kuzushita N Mita E Nakazuru S etal	2008	Hepatology2008，48，4：	1
	10	Optimal treatment change criteria for advanced gastric cancer with non-measurable peritoneal metastasis: symptom/tumor mark- er-based versus CT-based显示文摘	HASEGAWA H FUJITANI K NAKAZURU S	2014	Anticancer Res2014，34，9：	1
	11	Optimal treatment change criteria for advanced gastric cancer with non-measurable peritoneal metastasis:symptom/tumor marker-based versus CT-based显示文摘	Hasegawa H Fujitani K Nakazuru S	2014	Anticancer Res2014，34，9：	1
	12	Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine:Case report显示文摘Poorly differentiated endocrine carcinoma (PDEC) of the pancreas is a rare and aggressive tumor. First-line treatment is commonly a combination of etoposide and cisplatin, but there is no consensus regarding further treatment recommendations. In this report, we describe a case of pancreatic PDEC treated with gemcitabine as third-line chemotherapy. A 62-year-old man with pancreatic PDEC was administered etoposide plus cisplatin as first-line treatment; he then received irinotecan for tumor relapse. However, because irinotecan induced ileus in this patient, we chose gemcitabine as thirdline chemotherapy. After two cycles of gemcitabine (1000 mg/m2 on days 1, 8 and 15 every 4 wk), a partialtumor response was noted by computed tomography (approximately 68% reduction in tumor size). Our patient survived for 15 mo after diagnosis. This is a rare case of unresectable pancreatic PDEC, which showed a partial response to gemcitabine after the failure of two other regimens. Gemcitabine could be an effective treatment option for pancreatic PDEC that is resistant to other treatments.	Shoichi Nakazuru Toshiyuki Yoshio Shigeki Suemura Mari Itoh Manabu Araki Chiaki Yoshioka Makiyo Ohta Yuka Sueyoshi Takashi Ohta Hiroko Hasegawa Kaori Morita Takashi Toyama Noriyoshi Kuzushita Yoshinori Kodama Masayuki Mano Eiji Mita	2010	World Journal of Gastroenterology2010，16，30：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费